{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:40:38Z","timestamp":1792791638297,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1172","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the safety and long-term effectiveness of repeated ultraselective transarterial chemoembolization (rusTACE) using a 1.7-Fr-tip microcatheter in hepatocellular carcinoma (HCC) patients with portal vein tumour thrombus (PVTT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective analysis includes HCC patients with PVTT treated with rusTACE between May 2014 and July 2022. A 1.7-Fr-tip microcatheter was used to perform rusTACE for ultraselective embolization of the tumour-feeding artery. Treatment was repeated at least 2 times within 2\u2009months. Treatment responses, survival rates, adverse event, liver function, and tumour-feeding arteries were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty patients underwent rusTACE with a mean interval of 42\u2009days between treatments. RusTACE was well-tolerated. Median survival time was 26.1\u2009months, with 1-, 2-, 3-, and 5-year survival rates of 85.0%, 61.0%, 40.9%, and 24.6%, respectively. Complete response (CR) of PVTT was achieved in 75%. Among these, 35% maintained CR of PVTT throughout follow-up (mean, 25.0\u2009months). Univariate analysis showed prognostic factors included Child\u2013Pugh score 5, CR of PVTT, CR of systemic tumours at the end of rusTACE, and liver tumour burden &amp;lt;30%. In 17%, a peribiliary vascular plexus or communicating artery was identified as the tumour-feeding artery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>RusTACE is a safe and effective treatment option for HCC with PVTT in selected patients (Child\u2013Pugh class A). RusTACE showed a high CR rate and long overall survival. The short interval between treatments and ultraselective embolization of tumour-feeding arteries contributed to favourable outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge<\/jats:title>\n                  <jats:p>RusTACE can be safely performed in HCC with PVTT and has a high local control rate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjr\/tqaf112","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:20:51Z","timestamp":1748301651000},"page":"1290-1297","source":"Crossref","is-referenced-by-count":2,"title":["Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus"],"prefix":"10.1093","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-9745","authenticated-orcid":false,"given":"Akira","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University , Osaka 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University , Osaka 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Jogo","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University , Osaka 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7213-4740","authenticated-orcid":false,"given":"Etsuji","family":"Sohgawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University , Osaka 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Uchida-Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Takemura","sequence":"additional","affiliation":[{"name":"Department of Frontier Life-Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Kashiwara Municipal Hospital, Kashiwara 582-0005,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kaminou","sequence":"additional","affiliation":[{"name":"Department of Radiology, Tsukazaki Hospital, Himeji 671-1227,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University , Osaka 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2025081213174176400_tqaf112-B1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025081213174176400_tqaf112-B2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"2025081213174176400_tqaf112-B3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2025081213174176400_tqaf112-B4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"2025081213174176400_tqaf112-B5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"2025081213174176400_tqaf112-B6","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.3748\/wjg.v12.i47.7561","article-title":"Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus","volume":"12","author":"Minagawa","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025081213174176400_tqaf112-B7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2025081213174176400_tqaf112-B8","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","article-title":"Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis","volume":"16","author":"Georgiades","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"2025081213174176400_tqaf112-B9","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1007\/s00330-019-06157-0","article-title":"Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation","volume":"29","author":"Yang","year":"2019","journal-title":"Eur Radiol"},{"key":"2025081213174176400_tqaf112-B10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3748\/wjg.v27.i13.1330","article-title":"Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization","volume":"27","author":"Chen","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2025081213174176400_tqaf112-B11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB (Oxford)"},{"key":"2025081213174176400_tqaf112-B12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2025081213174176400_tqaf112-B13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jvir.2006.12.004","article-title":"Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil","volume":"18","author":"Miyayama","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"2025081213174176400_tqaf112-B14","volume-title":"General Rules for the Clinical and Pathological Study of Primary Liver Cancer","author":"Japan LCSGo","year":"1997","edition":"1st English ed"},{"key":"2025081213174176400_tqaf112-B15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1148\/radiology.147.2.6836115","article-title":"The peribiliary vascular plexus: the microvascular architecture of the bile duct in the rabbit and in clinical cases","volume":"147","author":"Cho","year":"1983","journal-title":"Radiology"},{"key":"2025081213174176400_tqaf112-B16","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jceh.2013.05.002","article-title":"Biliary tract anatomy and its relationship with venous drainage","volume":"4","author":"Ramesh Babu","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"2025081213174176400_tqaf112-B17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092596","article-title":"Pathophysiology and imaging findings of bile duct necrosis: a rare but serious complication of transarterial therapy for liver tumors","volume":"12","author":"Kobayashi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025081213174176400_tqaf112-B18","first-page":"1806","article-title":"Usefulness of CT volumetry for gastric varix before balloon-occluded retrograde transvenous obliteration","volume":"61","author":"Kageyama","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"2025081213174176400_tqaf112-B19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00270-020-02751-8","article-title":"Splenic vein diameter is a risk factor for the portal venous system thrombosis after partial splenic artery embolization","volume":"44","author":"Ogawa","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2025081213174176400_tqaf112-B20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jgh3.12230","article-title":"Assessment of tumor volume and density as a measure of the response of advanced hepatocellular carcinoma to sorafenib: application of automated measurements on computed tomography scans","volume":"4","author":"Yamamichi","year":"2020","journal-title":"JGH Open"},{"key":"2025081213174176400_tqaf112-B21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","article-title":"Hepatic artery embolization in 120 patients with unresectable hepatoma","volume":"148","author":"Yamada","year":"1983","journal-title":"Radiology"},{"key":"2025081213174176400_tqaf112-B22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12885-018-3989-2","article-title":"Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus","volume":"18","author":"Yang","year":"2018","journal-title":"BMC Cancer"},{"key":"2025081213174176400_tqaf112-B23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.surg.2018.06.025","article-title":"Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma","volume":"164","author":"Gon","year":"2018","journal-title":"Surgery"},{"key":"2025081213174176400_tqaf112-B24","doi-asserted-by":"crossref","first-page":"980214","DOI":"10.3389\/fonc.2022.980214","article-title":"Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a review","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"key":"2025081213174176400_tqaf112-B25","doi-asserted-by":"crossref","first-page":"821599","DOI":"10.3389\/fonc.2021.821599","article-title":"TACE plus lenvatinib versus TACE plus sorafenib for unresectable hepatocellular carcinoma with portal vein tumor thrombus: a prospective cohort study","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqaf112\/63362697\/tqaf112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/98\/1172\/1290\/63362697\/tqaf112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/98\/1172\/1290\/63362697\/tqaf112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:17:52Z","timestamp":1755019072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/98\/1172\/1290\/8150954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":25,"journal-issue":{"issue":"1172","published-online":{"date-parts":[[2025,5,26]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqaf112","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,26]]}}}